Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2008 Jan;53(1):242-7.
doi: 10.1007/s10620-007-9849-6. Epub 2007 Jun 5.

Serum interleukin-6, soluble interleukin-6 receptor and Crohn's disease activity

Affiliations
Comparative Study

Serum interleukin-6, soluble interleukin-6 receptor and Crohn's disease activity

Stéphane Nancey et al. Dig Dis Sci. 2008 Jan.

Abstract

The relationship between plasma interleukin-6 (IL-6) concentration and its soluble receptor in Crohn's disease (CD) is not well elucidated. Twenty healthy volunteers and 94 consecutive patients with CD (44 in relapse and 50 in remission) were studied. Plasma IL-6 concentrations in patients with active disease [80 +/- 9 pg/ml; mean +/- standard error of the mean (SEM)] were significantly higher than in patients with inactive disease (50 +/- 4 pg/ml; P < 0.001) or controls (3 +/- 1 pg/ml; P < 0.001). However, concentrations did not vary with the severity of CD attacks. Plasma concentrations of soluble interleukin-6 receptor (sIL-6R) in active-CD patients (77 +/- 5 ng/ml) did not differ significantly from those with inactive disease (82 +/- 5 ng/ml), while both groups had significantly raised concentrations compared with those of controls (58 +/- 6 ng/ml; P < 0.03 and P < 0.01, respectively). Plasma IL-6 concentrations correlated significantly with serum C-reactive protein (CRP) (r = 0.34; P < 0.001), whereas plasma sIL-6R concentrations did not. Taken together, these data suggest that, although IL6 and sIL6-R are both involved in the inflammatory process of CD, they are poor markers of disease activity.

PubMed Disclaimer

References

    1. Cytokine. 1995 Feb;7(2):142-9 - PubMed
    1. J Gastroenterol Hepatol. 1999 Oct;14(10):987-96 - PubMed
    1. Gastroenterology. 1993 May;104(5):1285-92 - PubMed
    1. Eur J Immunol. 1993 May;23(5):1078-82 - PubMed
    1. Gut. 2005 Apr;54(4):488-95 - PubMed

Publication types